Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Double-blind, Placebo-controlled Study of MEDI8968 in COPD
2011-002563-23Phase 2Completed
- Sponsor
- MedImmune
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing MEDI8968 with Placebo (2 arms). Primary endpoint: Rate of moderate or severe acute exacerbations of COPD (AECOPD). Started Nov 2011; status: completed.
02
Drugs
AMG 108
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-002563-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002563-23.